Vim & Vigor - Spring 2011 - Parrish Medical Center - (Page 40)

HEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS ROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST ENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST ROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN AMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY UMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS ECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT ETASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAPTREATMENT TRAVERSING TEST PROSTATE-SPECIFIC ANTIGEN EST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST CHEMOTHERAPY: A treatment involving ROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN chemical drugs that travel in the blood and slow Staging helps physicians explain where cancer is in the body and or stop cells from multiplying. AMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY how aggressive it is. “It can help patients understand their diagnoTIP: As with radiation therapy, everyone reacts UMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS sis in a standardized way,” says Gary Shelton, spokesman for the ECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TESTto chemotherapy treatment differently. If chemoPROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT Oncology Nursing Society. The TNM staging system, developed therapy causes ETASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHYnausea, eatPROSTATE-SPECIFIC ANTIGEN PAP TEST foods that are easy to by the American Joint Committee on Cancer, describes the cancer digest and be sure to keep food in your system, EST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST Shelton says. Tell your doctor if nausea contindiagnosis with three letters: ROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN ues. Medication may help, too. AMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY T: Describes the size of the tumor and whether it has spread to UMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS LUMPECTOMY: Removal of a portion of the nearby tissue ECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TESTbreast. “This breast cancer TEST BENIGN MALIGNANT PROSTATE-SPECIFIC ANTIGEN treatment makes N: Whether nearby lymph nodes are affected ETASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHYeasier and PROSTATE-SPECIFIC ANTIGEN reconstruction PAP TEST is generally less trauM: Whether the cancer has metastasized, or spread to distant parts matic for the patient,” Shelton says. EST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST of the body TIP: To reduce discomfort postsurgery, CARCINOGEN ROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMYask your doctor toPROGNOSIS RECURRENCE CHEMOTHERAPY AMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS show you arm exercises. And be sure to Numbers may be assigned to these letters PROSTATE-SPECIFIC purchase a UMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TESTto further explain the ANTIGEN TEST BENIGNcomfortable sports bra to wear after MALIGNANT METASTASIS PROGNOSIS the procedure. diagnosis. Each cancer type may have variations of this staging ECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT system RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN ETASTASIS PROGNOSISor subcategories, so always ask your cancer care specialist MASTECTOMY: Removal of the breast as a for explanation. EST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST part of breast cancer treatment. There are ﬁve ROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCEof mastectomy—simple, modiﬁed CARCINOGEN types CHEMOTHERAPY LUMPECTOMY radical, AMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASISpartial and subcutaneous. CHEMOTHERAPY radical, PROGNOSIS RECURRENCE UMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGNhave questionsMETASTASIS PROGNOSIS METASTASIS: When cancer spreads from one TIP: If you MALIGNANT about the procedure, part of the body to the MAMMOGRAPHY PAP TESTvisit breastcancer.org and search “mastectomy ECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN other, often through the PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT lymph system or bloodstream. what to expect.” ETASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TIP: There is usually more than one way to treat EST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST RADIATION THERAPY: Localized treatment cancer. Get a second opinion about your treatment ROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN that interrupts cell activity and “kills” cells. Side to determine all your options. AMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY effects of radiation therapy most often relate to UMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS PROGNOSIS: The chance of recovery or recur- the targeted area. “It’s important that patients ECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TESTtalk to their cancer care team TEST BENIGN MALIGNANT PROSTATE-SPECIFIC ANTIGEN about side effects rence of the disease. ETASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY due to treatment,” Shelton says. TIP: Tell your doctor how you’d like to receive they experience PAP TEST PROSTATE-SPECIFIC ANTIGEN EST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN to six weeks after radia-TEST TIP: You can feel tired up MAMMOGRAPHY PAP this information. Perhaps you want family memROSTATE-SPECIFIC ANTIGEN TEST BENIGNwith you, or maybe you’d rather be alone. tion therapy. Be sure to LUMPECTOMY during bers MALIGNANT METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPYget plenty of restCARCINOGEN and after treatment. Let your team know what you are MALIGNANT AMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN most comfort-METASTASIS PROGNOSIS RECURRENCE CHEMOTHERAPY able with. UMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS ECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST RECURRENCE: Cancer that has returned after ROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS a period of time when it was not detected. ECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST TIP: Ask your cancer care team about support Watch a video about common risk ROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS groups speciﬁcally for people who are diagnosed factors and lifestyle changes you can ECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN have different concerns TEST with a recurrence and MAMMOGRAPHY PAP make by visiting PMC’s new content ROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS and needs than newly diagnosed patients. portal, parrishmed.com/vimand ECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST vigoronline. To download PMC’s ROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS latest annual cancer report, visit ECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP TEST parrishmed.com/cancer. ROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS ECURRENCE CHEMOTHERAPY LUMPECTOMY CARCINOGEN MAMMOGRAPHY PAP 40 Vim & Vigor · SP R I N G 2 011 TEST BENIGN MALIGNANT METASTASIS PROGNOSIS EST PROSTATE-SPECIFIC ANTIGEN RECURRENCE CHEMOTHERAPY LUMPECTOMY ARCINOGEN MAMMOGRAPHY PAP TEST PROSTATE-SPECIFIC ANTIGEN TEST BENIGN MALIGNANT METASTASIS PROGNOSIS RECURRENCE Staging Your Cancer online Are You at Risk? http://www.breastcancer.org http://www.parrishmed.com/vimandvigoronline http://www.parrishmed.com/vimandvigoronline http://www.parrishmed.com/cancer

Table of Contents for the Digital Edition of Vim & Vigor - Spring 2011 - Parrish Medical Center

Vim & Vigor - Spring 2011 - Parrish Medical Center
Table of Contents
Tasty Tips
Opening Thoughts
Community Calendar
What’s New?
Watch Your Step
A Workout for Every Mood
Don’t Fail Your Heart
If Your Bones Could Talk
Healthy Travels
Over 40 and Fabulous
Do-It-Yourself Health?
Fighting Words
Balancing Act
Giving & Getting
Fitness & Wellness Go Hand in Hand
Stopping PAD in Its Tracks
Community Health
Foundation Focus
Ask the Expert

Vim & Vigor - Spring 2011 - Parrish Medical Center